Fundraising FoxNewpath Partners — 2023 Investments
4 investments dated 2023 · listed companies and verified rows first · show all
Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.
AI & Machine LearningBiotechMedical DevicesBoston, US
Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)Michael Rosbash, PhD(Founder & Advisor)Richa Saxena, PhD(Founder & Advisor)Stuart Schreiber, PhD(Founder & Advisor)Brian Safina(President & Chief Executive Officer)in
Co-investorsARCH Venture PartnersTaiho Ventures, LLC
nChroma Bio is a genetic medicines company developing in vivo therapies that pair genetic cargoes with targeted delivery technologies.
BiotechLongevityBoston, US
Angelo Lombardo(Founder)David R. Liu(Founder)J. Keith Joung(Founder)Jonathan S. Weissman(Founder)Luigi Naldini(Founder)Luke Gilbert(Founder)
Board seatThomas Cahill· per SEC Form D · $135M raise · filed Sep 2023
Co-investorsOUP (Osage University Partners)Wellington ManagementAtlas VentureCasdin CapitalGV (Google Ventures)
DermBiont develops SM-030, a topical drug candidate targeting melasma, a skin pigmentation disorder, by inhibiting PKC-beta to address the underlying cause of hyperpigmentation.
BiotechDigital HealthMedical DevicesBoston, US
Robert Brucker(Executive Officer)inKarl R. Beutner(Executive Officer, Director)inNichola Eliovits(Executive Officer, Director)inMax Dawson(Executive Officer)in
BoardWilder Ramsey(Director)inJennifer Lee(Director)
Board seatDaniel Yadegar· per SEC Form D · $45.3M raise · filed Nov 2024
Co-investorsCivilization Ventures Management, LlcJoyance PartnersOlive Tree CapitalStart CapitalToba CapitalValia Ventures+2 more
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Co-investorsAndreessen HorowitzARCH Venture PartnersiGlobe PartnersAgent CapitalAlexandriaCasdin Capital+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.